ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

被引：0
|
作者：
Sands, Jacob
Mandrekar, Sumithra J.
Oxnard, Geoffrey R.
Kozono, David E.
Hillman, Shauna L.
Dahlberg, Suzanne Eleanor
Sun, Zhuoxin
Chaft, Jamie E.
Govindan, Ramaswamy
Gerber, David E.
Gray, Jhanelle Elaine
Malik, Shakun M.
Mooney, Margaret M.
Janne, Pasi A.
Vokes, Everett E.
Kelly, Karen
Ramalingam, Suresh S.
Stinchcombe, Tom
机构：
[1] Lahey Hosp & Med Ctr, Boston, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[9] NCI, Rockville, MD USA
[10] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[11] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[12] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[13] Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9077
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Adjuvant Therapy in High-Risk Prostate Cancer
    Shevach, Jeffrey
    Chaudhuri, Parul
    Morgans, Alicia K.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 45 - 53
  • [32] Adjuvant Systemic Therapy for High-Risk Melanoma
    Cohen, Sonia
    Tanabe, Kenneth K.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (05) : 2568 - 2569
  • [33] Adjuvant Therapy for High-risk Endometrial Carcinoma
    Perera, J.
    Hoskin, P.
    CLINICAL ONCOLOGY, 2021, 33 (09) : 560 - 566
  • [34] Adjuvant systemic therapy in high-risk melanoma
    Blankenstein, Stephanie A.
    van Akkooi, Alexander C. J.
    MELANOMA RESEARCH, 2019, 29 (04) : 358 - 364
  • [35] Adjuvant therapy in high-risk colon cancer
    Bleiberg, H
    SEMINARS IN ONCOLOGY, 2000, 27 (05) : 48 - 59
  • [36] Postenucleation adjuvant therapy in high-risk retinoblastoma
    Honavar, SG
    Singh, AD
    Shields, CL
    Meadows, AT
    Demirci, H
    Cater, J
    Shields, JA
    ARCHIVES OF OPHTHALMOLOGY, 2002, 120 (07) : 923 - 931
  • [37] Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
    Merchant, Melinda S.
    Bernstein, Donna
    Amoako, Martha
    Baird, Kristin
    Fleisher, Thomas A.
    Morre, Michel
    Steinberg, Seth M.
    Sabatino, Marianna
    Stroncek, Dave F.
    Venkatasan, Aradhana M.
    Wood, Bradford J.
    Wright, Matthew
    Zhang, Hua
    Mackall, Crystal L.
    CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3182 - 3191
  • [38] Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients
    Zhang, Wei-Qiao
    Zhang, Qiao
    Tan, Li
    Guan, Zhi-Feng
    Tian, Feng
    Tang, Hong-Tao
    He, Kun
    Chen, Wei-Qiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
    Salans, Mia
    Courtney, Patrick Travis
    Yip, Anthony
    Murphy, James D.
    CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
  • [40] Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
    Kapoor, A.
    Gharajeh, A.
    Sheikh, A.
    Pinthus, J.
    CURRENT ONCOLOGY, 2009, 16 : S62 - S68
12345